section name header

Pronunciation

tye-A-ga-been

Classifications

Therapeutic Classification: anticonvulsants

Indications

REMS


Action

  • Enhances the activity of gamma-aminobutyric acid, an inhibitory neurotransmitter.
Therapeutic effects:
  • Decreased frequency of seizures.

Pharmacokinetics

Absorption: 90% absorbed following oral administration.

Distribution: Unknown.

Protein Binding: 96%.

Metabolism/Excretion: Mostly metabolized by the liver; 2% excreted unchanged in urine.

Half-Life: Without enzyme-inducing antiepileptic drugs: 7–9 hr; with enzyme-inducing antiepileptic drugs: 4–7 hr.

Time/Action Profile

(blood levels)

ROUTEONSETPEAKDURATION
POunknown45 minunknown





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

CV: chest pain, edema, hypertension, palpitations, syncope, tachycardia

Derm: alopecia, dry skin, rash, sweating

EENT: abnormal vision, ear pain, tinnitus

GI: abdominal pain, gingivitis, nausea, stomatitis

GU: dysmenorrhea, dysuria, metrorrhagia, urinary incontinence

Metab: weight gain, weight loss

MS: arthralgia, neck pain

Neuro: dizziness, drowsiness, nervousness, weakness, ataxia, cognitive impairment, confusion, difficulty concentrating, hallucinations, headache, mental depression, personality disorder, SUICIDAL THOUGHTS, tremors

Resp: dyspnea, epistaxis

Misc: allergic reactions, chills, lymphadenopathy

Interactions

Drug-drug:

Drug-Natural Products:

Route/Dosage

Availability

(Generic available)

Assessment

Toxicity and Overdose:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Gabitril